Immunic exercises its option for the exclusive worldwide license to imu-856 from daiichi sankyo co ltd

Immunic exercises its option for the exclusive worldwide license to imu-856 from daiichi sankyo co., ltd..immunic inc - intends to begin phase 1 clinical studies for group of compounds, designated by immunic as imu-856, in h1 2020.immunic - financial terms of agreement have not been disclosed.immunic - option & license agreement gives co exclusive rights to commercialization of imu-856 in all countries, including u.s., europe and japan.immunic - option agreement also includes exclusivity on a patent application filed by daiichi sankyo, covering imu-856's composition of matter.immunic - concurrent with option exercise, immunic will pay to daiichi sankyo a one-time upfront licensing fee.
IMUX Ratings Summary
IMUX Quant Ranking